undamentalytics Newsletter
Sign in

Black Diamond Therapeutics, Inc. income statement

In fiscal 2025, Black Diamond Therapeutics, Inc. reported revenue of $70.0m, operating income of $12.5m (a 17.9% margin) and net income of $22.4m, or $0.39 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202024Dec 20242025Dec 2025LTMJun 2026
Revenue0000700
Research and development72248513428
General and administrative2821271716
Operating income−9−29−70−7913−52
Interest expense—00———
Income tax00000—
Net income−9−35−67−7022−43
Diluted EPS−$0.29−$1.13−$2.05−$1.27$0.39−$0.74
Diluted shares (average)30m31m33m55m58m58m
EBITDA−9−29−70−7813−52

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Black Diamond Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Black Diamond Therapeutics, Inc.